Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of ARQ 501 in cancer patients
NCT00622063Phase 2Completed
- Start
- Dec 2006
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lapachone in cancer. Primary endpoint: Provide ongoing treatment with ARQ 501. Started Dec 2006; status: completed.
02
Drugs
lapachone
03
Conditions
cancer
Beyond the preview
Go deeper on NCT00622063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00622063.